T2 Biosystems, Inc. (TTOO) Stock Is An 52-Week High Flier

June 17, 2018 - By Peter Erickson

T2 Biosystems, Inc. (NASDAQ:TTOO) Logo

The stock of T2 Biosystems, Inc. (NASDAQ:TTOO) hit a new 52-week high and has $10.35 target or 8.00 % above today’s $9.58 share price. The 5 months bullish chart indicates low risk for the $403.51M company. The 1-year high was reported on Jun, 17 by Barchart.com. If the $10.35 price target is reached, the company will be worth $32.28M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 1.48% or $0.14 during the last trading session, reaching $9.58. About 758,349 shares traded or 26.30% up from the average. T2 Biosystems, Inc. (NASDAQ:TTOO) has risen 181.59% since June 17, 2017 and is uptrending. It has outperformed by 169.02% the S&P500.

Analysts await T2 Biosystems, Inc. (NASDAQ:TTOO) to report earnings on August, 2. They expect $-0.34 EPS, up 32.00 % or $0.16 from last year’s $-0.5 per share. After $-0.36 actual EPS reported by T2 Biosystems, Inc. for the previous quarter, Wall Street now forecasts -5.56 % EPS growth.

T2 Biosystems, Inc. (NASDAQ:TTOO) Ratings Coverage

Among 5 analysts covering T2 Biosystems (NASDAQ:TTOO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. T2 Biosystems had 10 analyst reports since January 25, 2018 according to SRatingsIntel. The company was maintained on Thursday, January 25 by H.C. Wainwright. The stock of T2 Biosystems, Inc. (NASDAQ:TTOO) has “Buy” rating given on Thursday, March 29 by H.C. Wainwright. H.C. Wainwright maintained the shares of TTOO in report on Wednesday, May 9 with “Buy” rating. H.C. Wainwright maintained the shares of TTOO in report on Wednesday, March 7 with “Buy” rating. The firm has “Buy” rating by Janney Capital given on Wednesday, May 9. Canaccord Genuity maintained T2 Biosystems, Inc. (NASDAQ:TTOO) rating on Wednesday, March 7. Canaccord Genuity has “Buy” rating and $7.0 target. As per Monday, February 12, the company rating was maintained by H.C. Wainwright. The company was upgraded on Friday, June 1 by Leerink Swann. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, May 30.

More notable recent T2 Biosystems, Inc. (NASDAQ:TTOO) news were published by: Seekingalpha.com which released: “T2 Biosytems: The Story Is Just Beginning” on June 03, 2018, also Benzinga.com with their article: “T2Biosystems Announces FDA Approval For Sepsis Test: ‘This Is A Game-Changer'” published on May 29, 2018, Globenewswire.com published: “T2 Biosystems Reports Granting of Inducement Awards” on June 06, 2018. More interesting news about T2 Biosystems, Inc. (NASDAQ:TTOO) were released by: Streetinsider.com and their article: “T2 Biosystems (TTOO) Announces Late-Breaking Data on T2Bacteria Panel Underscore Sepsis Prevention …” published on June 13, 2018 as well as Seekingalpha.com‘s news article titled: “T2 Biosystems: Still A Buy After The Rally” with publication date: June 15, 2018.

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. The company has market cap of $403.51 million. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. It currently has negative earnings. The firm also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens.

T2 Biosystems, Inc. (NASDAQ:TTOO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.